Boston Scientific, Mayo Clinic back new Minneapolis medtech incubator
Boston Scientific (NYSE:BSX) is joining the Mayo Clinic and the University of Minnesota in backing startup accelerator Gener8tor as it launches a medtech focused incubator in Minneapolis, according to a new report from the Minneapolis Star Tribune.
The newly launched accelerator will operate under a seven-week program that will support six new startups with a focus on medical technology, requiring no fees or equity and offered three times a year, according to the report.
Initial entrants into the incubator include wearable-focused medical tape maker ExpressionMed, cardiac rhythm and neuromod dev Kobara Medical, interventi...
Source: Mass Device - March 27, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Boston Scientific Mayo Clinic Source Type: news
UPDATE: Boston Scientific lays out $406m for NxThera which plans spin-out of cancer treatment tech
Updated to include commentary from NxThera prez & CEO Bob Paulson.
Boston Scientific (NYSE:BSX) said today that it laid out a $406 million deal for NxThera and its Rezūm benign prostatic hyperplasia device, which uses steam to ablate excess prostate tissue.
The deal calls for $306 million in up-front cash from Marlborough, Mass.-based Boston Scientific, with another $100 million in potential milestones over the next four years. Boston, which in December 2015 led a $40 million funding round for NxThera, said the existing investment means it will have to put $240 million down and another $85 million on the table i...
Source: Mass Device - March 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat Boston Scientific NxThera Inc. Source Type: news
March Madness: Boston Scientific Continues Buying Spree
Boston Scientific is set to acquire NxThera, a urology specialist, for about $406 million. The transaction consists of an upfront cash payment of $306 million, and up to an additional $100 million in potential commercial milestone payments over the next four years. The deal is set to close in the second quarter of 2018.
Maple Grove, MN-based NxThera has developed and commercialized the Rezūm system, which is a minimally invasive therapy for the treatment of symptoms arising from benign prostatic hyperplasia (BPH). The system was cleared by FDA in 2015 and has CE mark.
Treatment with the Rezūm system is typically perfor...
Source: MDDI - March 21, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
Boston Scientific Announces Agreement To Acquire NxThera
Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia
MARLBOROUGH, Mass., March 21, 2018 -- (Healthcare Sales & Marketing Network) -- Boston Scientific (NYSE: BSX) today announced that it ... Devices, Urology, Mergers & Acquisitions Boston Scientific, NxThera, Rezūm, benign prostatic hyperplasia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2018 Category: Pharmaceuticals Source Type: news
Benign prostatic hyperplasia —gaining insight and potential new treatment identified in mice
New information on the potential role of fibrosis in benign prostatic hyperplasia (BPH) could offer insights into how fibrosis occurs in other tissues. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news
Teleflex ’ s NeoTract wins expanded FDA indication for UroLift prostate device
Teleflex (NYSE:TFX) subsidiary NeoTract said yesterday that it won expanded indications from the FDA for its UroLift prostate treatment.
Previously approved for treating benign prostate hyperplasia in men 50 and over without an obstructive median lobe, the new indications open the treatment to patients 45 or older with an obstructive median lobe. UroLift uses tiny devices inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate.
“We are excited that more men with enlarged prostate are now eligible for treatment with the UroLift...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Regulatory/Compliance Urology Wall Street Beat NeoTract Teleflex Source Type: news
Procept BioRobotics raises $118m for Aquablation prostate treatment
Procept BioRobotics said today that it raised $118 million in an equity round it plans to use on the commercialization of its Aquablation treatment for benign prostate hyperplasia.
Redwood Shores, Calif.-based Procept said new backer Viking Global Investors led the round, joined by Perceptive Advisors and existing investors including CPMG.
The Aquablation treatment combines Procept’s Aquabeam – a high-pressure water jet used to remove prostate tissue without heating it – with imaging and surgical robotics technology. It won de novo clearance from the FDA last December; at the time, Procept said it ho...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Robotics Urology Wall Street Beat Procept BioRobotics Source Type: news
Medical News Today: What are the effects of an enlarged prostate on sex?
Learn about how benign prostatic hyperplasia can affect sexual function. We look at the effects and treatment options, including surgery, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 19, 2018 Category: Consumer Health News Tags: Sexual Health / STDs Source Type: news
Zenflow raises $31m in Series A
Urology medical device maker Zenflow said today it closed a $31.4 million Series A round of financing to support the development of minimally invasive devices designed to treat obstructive urinary symptoms related to benign prostatic hyperplasia.
The round was led by Invus Opportunities, F-Prime Capital Partners and Medical Technology Venture Partners and was joined by other new and existing investors, the San Francisco-based company said.
Zenflow said it has also received grant funding from the National Institutes of Health and the National Science Foundation.
The company’s first product is the Spring System device,...
Source: Mass Device - February 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Urology zenflow Source Type: news
NxThera touts 3-year Rez ūm trial results
NxThera today released three-year results from a trial of its Rezūm convective water vapor wave energy system, touting effective and durable relief from lower urinary tract symptoms for patients with benign prostatic hyperplasia.
The trial was co-authored by co-principal investigators Dr. Kevin McVary of Southern Illinois University School of Medicine and Dr. Claus Roehrborn of the University of Texas Southwestern Medical Center, and results were published in the January 2018 issue of the journal Urology.
“Rezūm warrants consideration as a first-line treatment for BPH due to the durability of LUTS relief out to th...
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Urology NxThera Inc. Source Type: news
Butterfly Medical wins CE Mark for in-office benign prostate hyperplasia device
Medical device developer Butterfly Medical said today it won CE Mark approval in the European Union for its device designed for the in-office treatment of benign prostate hyperplasia.
The Israel-based company’s device is designed to dilate the prostatic urethra without any surgical incisions or prostate tissue removal. The device then secures tightly to the prostate tissue to prevent migration to move the lobes of the prostate out of the way and improve urine flow.
“We are proud to bring a simple, non-surgical treatment option to the millions of men worldwide afflicted by BPH. With our Butterfly Medical devic...
Source: Mass Device - November 28, 2017 Category: Medical Devices Authors: Fink Densford Tags: Regulatory/Compliance Urology butterflymedical Source Type: news
Prostate problem? Take 2 nuts
By age 60, you have a 50/50 chance of having a clinically enlarged prostate. And it only gets worse every year. When your prostate isn’t functioning properly, it’s hard to enjoy life.
Traditional doctors give you two choices.
Go under the knife or you take Big Pharma’s drugs.
Either way, you have a good chance of ending up with your manhood on the line…
If you have surgery, there’s a big risk you’ll be saying goodbye to your sex life for good. The rate of impotence is a shocking 50 to 60% after prostate surgery.1
Big Pharma’s meds to shrink your prostate are no better. These synthetic drugs have a history ...
Source: Al Sears, MD Natural Remedies - October 19, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news
Teleflex closes $1B NeoTract buy
Teleflex (NYSE:TFX) said today that it closed its $1.1 billion acquisition of NeoTract and its UroLift prostate treatment.
The deal called for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said.
The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. NeoTract put up sales of roughly $51 million last year, up 178% over 2015, and is expected to post...
Source: Mass Device - October 3, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat NeoTract Teleflex Source Type: news
Procept BioRobotics treats first patients in Water II test of surgical robot
Procept BioRobotics announced today that the first patients were treated in its Water II Study, a clinical trial testing the safety and efficacy of Aquablation delivery by its surgical robotic AquaBeam System to treat benign prostatic hyperplasia.
The trials test the use of the system in prostates 80 to150 mL and will enroll 100 patients at up to 20 sites in the U.S. and Canada.
Read the full story on our sister site, The Robot Report.
The post Procept BioRobotics treats first patients in Water II test of surgical robot appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 27, 2017 Category: Medical Devices Authors: Alex Beall Tags: Biotech Research & Development Robotics Surgical Urology Procept BioRobotics Source Type: news
Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz
Title: Benign Prostatic Hyperplasia (Enlarged Prostate) QuizCategory: MedicineNet QuizCreated: 2/7/2012 3:29:00 PMLast Editorial Review: 9/20/2017 12:17:12 PM (Source: MedicineNet Mens Health General)
Source: MedicineNet Mens Health General - September 20, 2017 Category: Primary Care Source Type: news
